Business Context and Reporting Period
Company: Twist Bioscience Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: December 7, 2018
Reporting Period: Event-based update regarding ongoing litigation.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding litigation and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is a procedural update in the lawsuit filed by Agilent Technologies, Inc. against Twist Bioscience Corporation and its CEO, Ms. Emily Leproust:
- Amended Complaint Granted: On December 7, 2018, the Superior Court of California granted Agilent's motion to amend its complaint.
- New Defendants: The amended complaint adds Dr. Siyuan Chen (current employee) and Ms. Solange Glaize (former CFO) as defendants.
- New Claims: The complaint includes new claims for breach of contract and trade secret misappropriation against the new defendants, alongside amended allegations against the Company and Ms. Leproust.
- Discovery Ruling: The Court denied Agilent's motion for a protective order, meaning no limits were set on discovery.
- Trial Date: The Court set the trial to commence on February 24, 2020.
Guidance, Outlook, and Risks
Management Commentary: The Company and Ms. Leproust maintain they have substantial and meritorious defenses and intend to vigorously defend their position through trial and appellate stages if necessary.
Risks and Contingencies:
- Litigation Uncertainty: The outcome of the litigation is inherently uncertain.
- Material Adverse Effect: There is no assurance that the outcome of the case or the costs of litigation will not have a material adverse effect on the Company's business.
Unusual Items: None reported beyond the ongoing litigation proceedings.
Investor Verification Checklist
- Verify the specific allegations in the Second Amended Complaint filed by Agilent.
- Monitor the Company's investor relations website for the statement furnished as Exhibit 99.1.
- Track future filings for updates on discovery proceedings and trial preparations leading to the February 24, 2020 start date.
- Assess potential financial impact of litigation costs and potential damages in future quarterly reports.